Recent Updates
Recently added Catalysts

Ceftobiprole medocaril

Phase 3FDA approved

Staphylococcus Aureus Bacteremia | Small Molecules | Infectious Disease |Innoviva, Inc.|Trials Updated: Nov 10, 2026

Ceftobiprole medocaril development status

FDA approval on record Apr 3, 2024 as Zevtera
Approval holderIstx
ApplicationNDA218275
Highest phase Phase 3

Label indication ZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis ( 1.1 ), Adult patients with acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ), and Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial… FDA label

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment60

FDA Designations

No designations recorded

Ceftobiprole medocaril clinical trials

Ceftobiprole medocaril · 1 trial · 2 indications

Phase 3 1
NCT07929493A Study of Ceftobiprole Compared With Standard Antibiotic Treatment in Children With Staphylococcus Aureus Bacteremia (SAB) Infection, Including Right-sided Heart InfectionStaphylococcus Aureus Bacteremia
NOT YET_RECRUITING60 Analytics
PHASE3NOT YET_RECRUITING
A Study of Ceftobiprole Compared With Standard Antibiotic Treatment in Children With Staphylococcus Aureus Bacteremia (SAB) Infection, Including Right-sided Heart Infection
Staphylococcus Aureus BacteremiaUnlock trial analytics

Study Endpoints

Primary Endpoints

Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs)
Day 1 through last follow-up (LFU) [up to 11 weeks]
Percentage of participants with serious adverse events (SAEs)
Baseline through LFU [up to 11 weeks]
Percentage of participants with treatment-related adverse events (AEs)
Day 1 through LFU [up to 11 weeks]
Percentage of participants with adverse events of special interest (AESIs)
Baseline through LFU [up to 11 weeks]
Percentage of participants with adverse events (AEs) leading to discontinuation of study-drug treatment
Baseline through LFU [up to 11 weeks]
Percentage of participants with treatment-emergent abnormal hematology laboratory test results
Baseline through the end-of-treatment (EOT) visit [up to approximately 6 weeks]
Percentage of participants with treatment-emergent abnormal blood chemistry laboratory test results
Baseline through the EOT visit [up to approximately 6 weeks]
Percentage of participants with treatment-emergent abnormal urinalysis test results
Baseline through the EOT visit [up to approximately 6 weeks]
Change from baseline in body temperature
Baseline through LFU visit [up to 11 weeks]
Change from baseline in systolic blood pressure
Baseline through LFU visit [up to 11 weeks]
Change from baseline in diastolic blood pressure
Baseline through LFU visit [up to 11 weeks]
Change from baseline in respiratory rate
Baseline through LFU visit [up to 11 weeks]
Change from baseline in heart rate
Baseline through LFU visit [up to 11 weeks]

Secondary Endpoints

Percentage of All-Cause Mortality (ACM)
Through 28 days after EOT [up to approximately 10 weeks]
Percentage of new metastatic foci or other complications of SAB
Day 8 through test-of-cure (TOC) [up to approximately 8 Weeks]
Percentage of participants with Clinical Success at the TOC Visit
TOC visit [7-14 days after EOT]
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
CeftobiproleEXPERIMENTALParticipants randomized to this arm will receive intravenous (IV) ceftobiprole.
Standard-of-Care (SOC)ACTIVE_COMPARATORParticipants randomized to this arm will receive intravenous (IV) standard-of-care (SOC) antibiotic treatment selected according to local guidelines or site-specific standard practice.

Interventions

NameTypeDescription
Ceftobiprole medocaril sodiumDRUGCeftobiprole dosing is based on age/body weight and renal function and given at 7.5 mg/kg, 10 mg/kg, or 15 mg/kg (equivalent to 10 mg/kg, 13.3 mg/kg, or 20 mg/kg respectively of ceftobiprole medocaril sodium) q8h, q12h or q24h up to a maximum of 500 mg (equivalent to 667 mg of ceftobiprole medocaril sodium), with all doses infused over 2 hours.
Standard of Care (SOC)DRUGDosage is per local product label based on the participant's age/body weight, and, if applicable, renal function.
Unlock Study Design Details

Eligibility Criteria

Age Range3 Days to 17 Years
SexALL
Healthy VolunteersNo

Key Inclusion Criteria: * Pediatric age from birth to \< 18 years old, with body weight ≥ 3.7 kg at the time of consent. Participants in the birth to \< 2-year-old cohort should have a gestational age ≥ 37 weeks and postnatal age ≥ 3 days * Parent(s) or legal guardian(s) have provided documented in...

Unlock Eligibility Criteria